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Aims: Socioeconomic changes in Latin American countries have led to an increased preva-
lence of type 2 diabetes (T2D). We examined the effects of exenatide twice daily (BID) or
insulin lispro, each added to insulin glargine, in Latin American patients with T2D.
Methods: This was a subgroup analysis of patients from Argentina and Mexico in the 4B
study (N = 114). Patients with glycated hemoglobin (HbA1c) of 7.0–10.0% (53–86 mmol/mol)
after 12 weeks of intensive basal insulin optimization were randomized to exenatide BID or
thrice-daily insulin lispro added to insulin glargine and metformin.
Results: After 30 weeks, addition of exenatide BID or insulin lispro resulted in significant
(P < 0.0001) reductions in HbA1c (exenatide BID: 0.9% [10 mmol/mol]; insulin lispro:
1.2% [13 mmol/mol]). Weight was stable in the exenatide BID group (0.1 kg) and
increased significantly (+3.4 kg; P < 0.0001) with insulin lispro. Major and minor hypo-
glycemia occurred less frequently (40 vs. 253 events) with exenatide BID compared with
insulin lispro. Gastrointestinal adverse events of nausea, diarrhea, and vomiting occurred
more frequently with exenatide BID than with insulin lispro.
Conclusions: Both exenatide BID and prandial insulin lispro, each added to basal insulin
glargine, were effective at reducing HbA1c in Latin American patients. Treatment with
exenatide BID resulted in stable weight but more gastrointestinal adverse events. Treat-
ment with insulin lispro resulted in weight gain and an increased risk of hypoglycemia.
These findings support the addition of exenatide BID to insulin glargine as an option for
Latin American patients unable to achieve glycemic control on basal insulin alone.
 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ires 1419,
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The population of patients with type 2 diabetes is heteroge-
neous, with patients differing in key aspects such as the rate
of disease progression and presence of obesity [1]. Since sep-
arate phenotypes of type 2 diabetes have not been fully iden-
tified, subgroups are often defined based on geographic
location. Populations from specific regions may share unique
genetic and/or dietary characteristics that affect glycemic
control and may therefore impact the response to therapy.
Characterizing responses to treatment within patient sub-
groups from early to late stages of diabetes may inform indi-
vidualized treatment decisions.
In Latin American countries, socioeconomic changes have
led to lifestyle changes and subsequent increases in the
prevalence of obesity, type 2 diabetes, and cardiovascular
disease [2]. The average prevalence of type 2 diabetes in South
and Central American countries was reported as 8.0% in 2013
and is expected to reach 9.8% by 2035 [3], while in Mexico, the
prevalence of type 2 diabetes was reported as 14.4% in 2006
[4]. In light of these trends, evaluation of glucose-lowering
treatment choices in Latin American patients is of interest,
particularly for therapeutic options with novel mechanisms
of action.
In a multinational, multicenter study of patients who
were unable to achieve glycemic control after 12 weeks of
basal insulin optimization (BIO) and metformin, the Basal
Insulin Glargine + Exenatide BID vs. Basal Insulin Glargine
+ Bolus Insulin Lispro (4B) study group found that the
addition of the glucagon-like peptide-1 receptor agonist
(GLP-1RA) exenatide twice daily (BID) produced a compara-
ble reduction in glycated hemoglobin (HbA1c) to that of
prandial insulin lispro [5]. Treatment with exenatide BID
was also associated with weight loss, a reduction in systolic
blood pressure, and greater treatment satisfaction, despite
an increased prevalence of gastrointestinal adverse events
(AEs). Treatment with insulin lispro was associated with
weight gain and a higher rate of hypoglycemia. Differences
in the effects of these treatments are likely due to their
differing mechanisms of action; GLP-1RAs increase
glucose-dependent insulin release and decrease glucose-
dependent glucagon release, delay gastric emptying, and
reduce food intake [6]. The glucose-dependent nature of
GLP-1RAs improves glycemic control at elevated blood
glucose levels, without increasing the risk of hypoglycemia.
Insulin stimulates glucose reuptake in skeletal muscle and
glycogenesis in the liver and inhibits glucagon secretion
[7]. When administered exogenously, insulin reaches high
concentrations in peripheral tissue, which increases the risk
for hypoglycemia and weight gain.
Here, we conducted a subgroup analysis of Latin Ameri-
can patients enrolled in the primary 4B study to evaluate
the safety and efficacy of exenatide BID compared with
insulin lispro, added-on to basal insulin glargine and met-
formin, in Latin American patients unable to achieve glyce-
mic control with titrated insulin glargine and metformin
alone.2. Materials and methods
2.1. Study design
This was a post hoc subgroup analysis of Latin American
patients who participated in the open-label, randomized, con-
trolled, noninferiority 4B study (NCT00960661), the methods
of which have previously been reported [5]. Briefly, male and
female patients aged 18 years with type 2 diabetes currently
treated with insulin glargine and metformin (with or without
sulfonylurea), and with an HbA1c of 7.0–10.0% (53–86 mmol/
mol) and a body mass index of 25–45 kg/m2 were eligible for
enrollment. Sulfonylurea use was discontinued upon study
entry. Type 2 diabetes was diagnosed by World Health Organi-
zation criteria [8]. Islet cell antibodies, C-peptide, or insulin
levels were not tested to further classify the type of diabetes.
Patients with medical conditions that had the potential to
impact patient safety, such as clinically significant cardiovas-
cular disease (New York Heart Association Class III or IV for
congestive heart failure or judged by the investigator to be
exclusionary), 1 episode of major hypoglycemia in the
6 months prior to enrollment, a fasting triglyceride level of
5.7 mmol/L, or a history of confirmed pancreatitis were
excluded from the study. For this subgroup analysis of Latin
American patients, safety and efficacy data were pooled from
the study centers in Mexico and Argentina and not from self-
identified race.
The study consisted of a 12-week BIO phase, followed by
randomization and a 30-week intervention phase [5]. During
the BIO phase, insulin glargine was titrated to maintain a
self-monitored fasting glucose (FG) level of 5.6 mmol/L or
lower without hypoglycemia (ie, blood glucose level of
<3.0 mmol/L). At the end of the BIO phase, patients unable
to achieve an HbA1c of 7.0% (53 mmol/mol) or less were eligi-
ble to be randomized and to continue in the study. To mini-
mize hypoglycemia associated with medication changes,
patients randomized to the exenatide BID group and with
an HbA1c of 8.0% (64 mmol/mol) reduced their insulin
glargine dose by 10%. Exenatide BID was added at a dose
of 5 lg BID for the first 4 weeks and 10 lg BID thereafter, taken
with the two largest meals (breakfast or lunch and dinner) at
least 6 h apart. Similarly, patients randomized to insulin lis-
pro with an HbA1c of 8.0% (64 mmol/mol) reduced their
insulin glargine dose by one-half to one-third and added the
equivalent dose (one-half or one-third of their total glargine
dose) in insulin lispro, so that the total insulin dose remained
the same. Insulin lispro was dosed three times daily prior to
each meal (breakfast, lunch, and dinner). Throughout the
intervention phase, insulin glargine was titrated as in the
BIO phase. A four-point self-monitored blood glucose profile,
recorded with a Roche plasma-equivalent (Roche Diagnostics,
Indianapolis, IN, USA) or Roche International Federation of
Clinical Chemistry and Laboratory Medicine plasma-
equivalent referent meter (provided to all patients), was
collected twice weekly. Measurements were taken
pre-breakfast, pre-lunch, pre-dinner, and before bed. Insulin
lispro was titrated based on self-monitored pre-meal glucose
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Patients continued insulin glargine and metformin in addi-
tion to their randomized treatment.
The original study protocol was developed in accordance
with the Declaration of Helsinki and Good Clinical Practice
guidelines and approved by the ethics and regulatory com-
mittees and institutional review boards [5]. All patients pro-
vided written informed consent.
2.2. Study outcomes
The primary outcome was the change in HbA1c from baseline
(randomization) to endpoint (30 weeks) [5]. Key secondary
outcomes included the percentage of patients who achieved
HbA1c targets (6.5% and 7.0% [48 and 53 mmol/mol]),
FG, 2-h postprandial glucose excursions, weight, and insulin
dose. Waist circumference, systolic and diastolic blood pres-
sure, and cholesterol were also recorded. Safety was assessed
by monitoring of hypoglycemic events and AEs. Minor hypo-
glycemia was defined as any incidence of hypoglycemia
symptoms with a concurrent fingerstick blood glucose level
of <3.0 mmol/L. Major hypoglycemia included symptoms
such as loss of consciousness, seizure, or a severe impairment
requiring the assistance of another person.
2.3. Statistical analyses
Efficacy was assessed using the per-protocol (PP) population,
defined as all randomized patients who completed the study
and met all inclusion and no exclusion or discontinuation cri-
teria. Safety was assessed using the as-treated population,
defined as all randomized patients who received at least
one dose of study medication, according to the treatment
received. The intention-to-treat (ITT) population was defined
as all randomized patients receiving at least one dose of study
drug, according to the randomized treatment assigned,
regardless of the treatment actually received. For this analy-
sis, the as-treated and ITT populations were identical.
Changes in continuous variables were reported as arith-
metic mean ± standard deviation (SD) or standard error as
noted, and categorical variables were calculated as frequency
and percent of patients. Missing values were imputed using
the last observation carried forward method. P-values for
comparison to baseline were derived from a paired t-test
compared with baseline data. The study was not powered to
detect treatment differences in this subpopulation; therefore,
between-treatment comparisons were not assessed.
3. Results
3.1. Patient demographics and disposition
In the primary study population, 627 patients were random-
ized and received at least one dose of study treatment (ITT
and as-treated populations) [5]. Of these patients, the Latin
American ITT (and as-treated) subpopulation included 114
patients (Mexico, n = 61; Argentina, n = 53) (Supplementary
Fig. 1). In this subpopulation, more patients discontinued
treatment in the insulin lispro group (n = 12) than in theexenatide BID group (n = 6). The Latin American PP population
included 91 patients: 48 patients received exenatide BID and
43 received insulin lispro, both added to insulin glargine.
Baseline characteristics of the Latin American population
were generally similar between patients treated with
exenatide BID and those treated with insulin lispro (Table 1),
including age (59.1 ± 10.4 years [mean ± SD] for the overall
PP population), weight, glycemic parameters, and blood pres-
sure. However, more white and male patients were included
in the exenatide BID-treated group. The overall mean ± SD
duration of diabetes was 12.6 ± 7.2 years.
3.2. Efficacy
Both exenatide BID and insulin lispro added to insulin glar-
gine improved glycemic control, as indicated by measures of
HbA1c, FG, and postprandial glucose. Significant reductions
in HbA1c from baselinewere observed in both groups by week
2 (Fig. 1A) and throughout the remainder of the 30-week inter-
vention phase. At endpoint (the primary outcome measure),
mean ± SD HbA1c change was 0.9% ± 1.0% (10 ± 11 mmol/
mol) for patients treated with exenatide BID and 1.2% ± 1.0%
(13 ± 11 mmol/mol) for patients treated with insulin lispro
(P < 0.0001 vs. baseline for both groups). A numerically greater
proportion of patients treated with exenatide BID and insulin
glargine than insulin lispro and insulin glargine achieved
HbA1c targets (HbA1c < 7.0% [<53 mmol/mol]: 50.0% vs.
46.5%; HbA1c  6.5% [48 mmol/mol]: 35.4% vs. 20.9%). A
small, nonsignificant reduction in FG versus baseline was
observed for both groups throughout the treatment period
(Fig. 1B), with a mean ± SD change of 0.15 ± 3.1 mmol/L with
exenatide BID added-on to insulin glargine and 0.17
± 3.4 mmol/L with insulin lispro added-on to insulin glargine
at endpoint. Over the 30-week intervention phase, similar
reductions in post-breakfast and post-lunch glucose excur-
sions were observed in patients receiving exenatide BID and
insulin lispro, both added to insulin glargine; however, treat-
ment with insulin lispro was associated with a greater
decrease in the post-dinner glucose excursion than that of
exenatide BID (Fig. 1C).
Measures of weight, waist circumference, and total insulin
dose demonstrated differing effects of the two treatments. At
endpoint, patients treatedwith exenatideBIDplus insulin glar-
gine had approximately maintained their weight, with mean
± SD weight loss of 0.1 ± 2.6 kg (P = 0.87), while patients trea-
ted with insulin lispro plus insulin glargine had a significant
weight gain of +3.4 ± 2.8 kg (P < 0.0001) (Fig. 1D). A small, non-
significant mean ± SD decrease in waist circumference with
exenatideBID treatment (0.25 ± 6.86 cm) andanonsignificant
mean ± SD increase with insulin lispro treatment (+0.73
± 5.28 cm) was observed. At baseline, the mean daily insulin
glargine dose was slightly lower in the exenatide BID group
compared with the insulin lispro group (Table 1). At endpoint,
the mean ± SD insulin glargine dose was slightly higher for
patients treated with exenatide BID added-on to insulin glar-
gine (57.6 ± 30.3 units) than with insulin lispro added-on to
insulin glargine (55.0 ± 20.2 units). The total mean ± SD insulin
dose was 57.6 ± 30.2 units for the exenatide BID group and
113.6 ± 67.9 units for the insulin lispro group at endpoint.
Table 1 – Baseline demographics and characteristics (per-protocol population).
Parameter Exenatide BID + insulin glargine (n = 48) Insulin lispro + insulin glargine (n = 43)
Age, y 59.5 ± 10.2 58.8 ± 10.7
Male, n (%) 21 (43.8) 14 (32.6)
Race, n (%)*
White 36 (75.0) 25 (58.1)
American Indian or Alaskan Native 12 (25.0) 18 (41.9)
Body weight, kg 82.0 ± 12.4 81.7 ± 14.0
BMI, kg/m2 31.3 ± 4.6 32.1 ± 4.6
Waist circumference, cm 105.5 ± 10.3 105.3 ± 11.8
HbA1c, % (mmol/mol) 8.0 ± 0.8 8.3 ± 1.0
(64 ± 9) (67 ± 11)
Fasting glucose, mmol/L 6.1 ± 2.4 6.6 ± 2.7
Total cholesterol, mmol/L 4.6 ± 0.9 4.9 ± 0.9
Systolic blood pressure, mmHg 131.3 ± 16.3 128.8 ± 18.4
Diastolic blood pressure, mmHg 76.3 ± 9.0 77.2 ± 10.9
Duration of diabetes, y 11.7 ± 6.4 13.7 ± 8.0
Insulin glargine dose, U 61.7 ± 24.5 67.3 ± 28.4
Background glucose-lowering therapy, n (%)
Insulin glargine only 0 (0.0) 1 (2.3)
Insulin glargine + metformin 48 (100.0) 42 (97.7)
Data are mean ± standard deviation, unless otherwise noted.
BID, twice daily; BMI, body mass index; HbA1c, glycated hemoglobin.
* One race was chosen per person.
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Cardiovascular risk markers were also assessed. Treatment
with exenatide BID added-on to insulin glargine did not sig-
nificantly change systolic blood pressure (mean ± SD, 0.46
± 16.04 mmHg; P = 0.84), while treatment with insulin lispro
added-on to insulin glargine was associated with a significant
(P = 0.044) increase in systolic blood pressure (mean ± SD,
+5.16 ± 16.28 mmHg). Diastolic blood pressure did not signifi-
cantly change for either treatment group (exenatide BID
added-on to insulin glargine: mean ± SD, +1.17 ± 9.58 mmHg;
insulin lispro added-on to insulin glargine:+1.86 ±
9.71 mmHg). Treatment with exenatide BID or insulin lispro,
both added to insulin glargine, did not significantly
impact total cholesterol; the mean ± SD change was +0.04 ±
0.65 mmol/L with exenatide BID and +0.08 ± 0.71 mmol/L with
insulin lispro.
3.4. Safety and tolerability
Safety was assessed by monitoring of hypoglycemia and AEs.
Although statistical comparisons between the exenatide BID
and insulin lispro groups would be inappropriate, hypo-
glycemia events appeared to occur numerically less fre-
quently in patients treated with exenatide BID added-on to
insulin glargine than with insulin lispro added-on to insulin
glargine (Table 2). This was true for both nocturnal and day-
time events. The AE profile was consistent with that of the
primary study [5]. The most common AEs were gastrointesti-
nal and occurred more frequently with exenatide BID
added-on to insulin glargine (Table 3), with the exception of
pharyngitis, which occurred in six patients in each treatment
group. Serious AEs occurred in three patients in the exenatideBID plus insulin glargine group: osteomyelitis, congestive
heart failure (both resolved), and hemorrhagic stroke (resulted
in death; considered unrelated to study treatment by the
investigator). Serious AEs occurred in two patients in the insulin
lispro plus insulin glargine group: acute myocardial infarction
(resolved) and chronic cholecystitis (resolution unknown).
4. Discussion
Individualized therapy is important throughout the course of
type 2 diabetes. This analysis examined patients at a later
stage of type 2 diabetes who were unable to achieve glycemic
control after 12 weeks with basal insulin titration. For
patients unable to achieve glycemic control with either oral
treatment or basal insulin, relatively few options are avail-
able. Current international guidelines recommend the use of
combination injectable therapy, with combinations including
either a GLP-1RA or short-acting prandial insulin added to
basal insulin [9]. In Latin America, GLP-1RAs became available
in 2009 [10]. In 2010, the Latin American Diabetes Association
(LADA), consisting of representation from 17 different Latin
American countries, developed a position statement regard-
ing the management of type 2 diabetes. While the LADA rec-
ognized the benefits of treatment with GLP-1RAs, including
the reduced risk of hypoglycemia, they noted a need for fur-
ther studies examining the long-term safety and efficacy of
GLP-1RAs. Since then, several studies have confirmed the
long-term safety and efficacy of GLP-1RAs in the treatment
of type 2 diabetes in international and US populations
[11–13]. In addition, the LADA highlighted the unique chal-
lenges that face patients and physicians in Latin America
and noted that the quality of diabetes care is dependent on
geographic factors [10].
Fig. 1 – Efficacy results in Latin American patients treated with exenatide BID or insulin lispro added to insulin glargine and
metformin in the per-protocol population. A. Mean change (±SE) in HbA1c. B. Mean change (±SE) in fasting glucose. C. Mean
(±SE) 2-h postprandial glucose excursions. D. Mean change (±SE) in body weight. *P < 0.05; †P < 0.01; P < 0.001; §P < 0.0001;
P-values are derived from paired t-tests comparedwith baseline values. an = 42 at baseline; bn = 47 at week 12; cn = 41 at week
2; dn = 40 post-lunch and post-dinner; en = 29 post-dinner. BID, twice daily; HbA1c, glycated hemoglobin; IG, insulin glargine;
SE, standard error.
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BID to titrated insulin glargine in Latin American patients, we
identified a patient subgroup from the 4B study based on site
geography. The reduction in HbA1c was comparable amongTable 2 – Incidence of hypoglycemic events during the interven
Exenatide BID + insulin g
Incidence, n (%)
Major + minor 17 (30.4)
Major 0 (0.0)
Nocturnal (major + minor) 12 (21.4)
Daytime (major + minor) 7 (12.5)
Number of events, n
Major + minor 40
Major 0
Nocturnal events (major + minor) 26
Daytime events (major + minor) 14
BID, twice daily.patients treated with exenatide BID and insulin lispro, each
added on to insulin glargine. Further, patients treated with
exenatide BID maintained a stable weight throughout the
intervention phase, whereas patients treated with insulintion phase (as-treated population).
largine (n = 56) Insulin lispro + insulin glargine (n = 58)
29 (50.0)
4 (6.9)
23 (39.7)
23 (39.7)
253
6
98
155
Table 3 – Adverse events occurring in 10% of patients treated with exenatide BID or insulin lispro added to insulin glargine
(as-treated population).
Event, n (%) Exenatide BID + insulin glargine (n = 56) Insulin lispro + insulin glargine (n = 58)
Nausea 18 (32.1) 1 (1.7)
Diarrhea 11 (19.6) 5 (8.6)
Vomiting 8 (14.3) 1 (1.7)
Pharyngitis 6 (10.7) 6 (10.3)
BID, twice daily.
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stable with exenatide BID, but increased with insulin lispro
treatment. Hypoglycemia appeared to occur less frequently
and gastrointestinal AEs appeared to occur more frequently
with exenatide BID than with insulin lispro. Thus, the results
of this subgroup analysis support the use of exenatide BID in
Latin American patients unable to achieve glycemic control
on titrated basal insulin.
Though we attempted to identify a unique subgroup of
patients with type 2 diabetes based on site geography—in this
case patients from Latin America—it is unclear whether this
patient population is meaningfully different from the whole
of the 4B study population. Approximately 50% of patients
in the primary study were male, whereas approximately
30% to 40% of patients in the current analysis were male [5].
All patients in the subgroup self-identified as white or
American Indian or Native Alaskan, while the primary popu-
lation included patients who identified as African American
and Asian as well. Also, among exenatide BID-treated
patients, baseline HbA1c was lower for the current analysis
(8.0% [64 mmol/mol]) than in the primary population (8.3%
[67 mmol/mol]). Otherwise, baseline characteristics were
similar among patients.
For exenatide BID-treated patients, the reduction in HbA1c
in the Latin American subgroup (0.9% [10 mmol/mol]) was
numerically slightly smaller than in the primary study popu-
lation (1.1% [12.4 mmol/mol]). This difference may be
related to lower baseline HbA1c rather than a difference in
the treatment response, as higher baseline HbA1c is a strong
predictor of greater change in HbA1c in response to exenatide
BID treatment [14,15]. The change in HbA1c was comparable
for patients treated with insulin lispro: 1.2% (13 mmol/
mol) among Latin American patients and 1.1% (12 mmol/
mol) in the primary population [5]. Patients in the exenatide
BID group lost less weight compared with the primary study
population, and patients in the insulin lispro group had
greater weight gain compared with that of the overall study
population. In the primary study, systolic blood pressure sig-
nificantly decreased with exenatide BID treatment. However,
in this subgroup analysis, the decrease from baseline in sys-
tolic blood pressure with exenatide BID treatment did not
reach significance. In a separate meta-analysis of 16 random-
ized controlled clinical trials (seven of which compared the
effects of exenatide BID to placebo), treatment with exenatide
BID significantly (P < 0.00001) reduced systolic blood pressure
(5.24 mmHg; 95% confidence interval: 6.88, 3.59) [16].
Thus, the nonsignificant findings for systolic blood pressure
in this study may be related to the small sample size of thissubgroup analysis and a lack of statistical power to determine
a difference. Notwithstanding differences noted above, the
efficacy and safety findings of this subgroup analysis are gen-
erally consistent with the findings of the primary study and
support the use of exenatide BID added to basal insulin in
Latin American patients unable to achieve glycemic control
with titrated basal insulin.
Previous studies in a Latin American population have
found a similar response to exenatide BID and other
GLP-1RAs as in the current subgroup analysis. A two-arm
study of 377 Latin American patients (from Brazil and Mexico)
compared the effects of taking exenatide BID without insulin
glargine either before breakfast and dinner or before lunch
and dinner [17]. At the start of this earlier study, patients con-
tinued their pretrial oral medication, including metformin,
sulfonylureas, and/or thiazolidinediones. Compared to the
patients in the current analysis, patients in this study were
slightly younger, had a higher baseline HbA1c, and were not
taking insulin. After 12 weeks of treatment, HbA1c and mean
body weight significantly decreased with the administration
of exenatide BID both before breakfast and dinner and before
lunch and dinner [17]. FG decreased nonsignificantly with
exenatide BID administration before lunch and dinner but
was significantly reduced with administration before break-
fast and dinner. The reductions in HbA1c, FG, and weight
were larger than that of the current analysis but demonstrate
the consistency of exenatide BID in improving glycemic con-
trol and weight in Latin American patients. Furthermore, a
pooled analysis of 16 randomized clinical studies, lasting
12–30 weeks in duration, found similar results for Hispanic
patients with type 2 diabetes treated with exenatide BID
[18]. Patients were stratified for analysis by various character-
istics, including race (white, black, Asian, or Hispanic).
Among Hispanic patients (n = 232), the reduction in HbA1c
was comparable to that of the current analysis, while reduc-
tions in FG, weight, and systolic blood pressure were greater
in the pooled analysis than in the current subgroup analysis.
An additional post hoc analysis of four clinical studies found
26 weeks of treatment with the GLP-1RA liraglutide to result
in similar reductions in HbA1c and body weight for Latino/
Hispanic patients (n = 323) and non-Latino/Hispanic patients
[19]. Together with these studies, this subgroup analysis
demonstrates the consistent effects of GLP-1RA treatment
for Latin American patients.
In response to the 4B study, international guidelines were
updated to include the use of GLP-1RAs as an option for
patients requiring combination injectable therapy [9]. The
consistency of the findings of the subgroup analysis to the
44 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 2 2 ( 2 0 1 6 ) 3 8 –4 5primary 4B study and additional studies of exenatide BID in
Latin American patients suggests that the guideline recom-
mendations may be applicable to Latin American patients.
Limitations of the current analysis include the small sam-
ple size and the post hoc nature of the analysis. The current
study of Latin American patients was limited to patients from
Mexico and Argentina andwas not assessed according to self-
identified race. However, only a single race (white, Asian,
black/African American, or American Indian/Alaskan Native)
was allowed for self-identification; therefore, racial identity
may not have been completely captured, and it is possible
that subpopulations with different responses were not
included. Patient self-identification as Hispanic or not His-
panic was not recorded. The subgroup population was also
not racially balanced. The selection criteria for the primary
study excluded patients with certain medical conditions; as
such, patients with complex conditions may respond differ-
ently than those examined in the present analysis.
Future studies in Latin American patients would help to
better establish the effects of exenatide BID in this popula-
tion. Real-world studies have been conducted in American
[20] and European [21] patients and support the efficacy and
safety of exenatide BID. A prospective study or a registry
study that specifically examines the effects of exenatide BID
in a larger sample of Latin American patients, as well as addi-
tional randomized controlled trials, would help to validate the
current findings.5. Conclusions
This subgroup analysis of Latin American patients unable to
achieve glycemic control with titrated basal insulin glargine
and metformin alone found that the addition of exenatide
BID resulted in a comparable reduction in HbA1c to that of
insulin lispro, but without any associated weight gain. A
lower incidence of hypoglycemia and higher rates of gastroin-
testinal AEs in patients receiving exenatide BID were also
observed. Given the consistency of these results with the pri-
mary study, our findings support the efficacy and safety of
exenatide BID added to basal insulin and metformin in Latin
American patients with inadequate glycemic control.Author contributions
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